Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 2

Conditions

Venous Thromboembolism 2Neoplasms 2Venous Thrombosis 1Pulmonary Embolism 1Embolism 1

Interventions

Epoetin Alfa 38Darbepoetin alfa 30epoetin beta 10Rivaroxaban 9olaparib 5eltrombopag 5apixaban 5Heparin, Low-Molecular-Weight 5pegylated granulocyte colony-stimulating factor 4pegfilgrastim 4emicizumab 4Gemcitabine 4Filgrastim 4Dalteparin 4Cyclophosphamide 4AP 1903 reagent 4romiplostim 3peginesatide 3luspatercept 3hetrombopag 3hematide 3Vancomycin 3ON 01910 3Enoxaparin 3Azacitidine 3ACE-011 3venetoclax 2telapristone acetate 2roxadustat 2iron isomaltoside 1000 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × edoxaban × Classical hematology × Clear all
NCT04618913 2026-05-26

VICTORIE

Pfizer

Active not recruiting
1 enrolled
Classical hematology

Embolism, Neoplasms, Venous Thromboembolism

NCT02073682 2019-03-06

Cancer Venous Thromboembolism (VTE)

Daiichi Sankyo

Phase 3 Completed
1,046 enrolled 24 charts
Classical hematology

Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡